Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Hepatology ; 64(3): 880-93, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27081925

RESUMO

UNLABELLED: Biliary atresia, the most common indication for pediatric liver transplantation, is a fibrotic disease of unknown etiology affecting the extrahepatic bile ducts of newborns. The recently described toxin biliatresone causes lumen obstruction in mouse cholangiocyte spheroids and represents a new model of biliary atresia. The goal of this study was to determine the cellular changes caused by biliatresone in mammalian cells that ultimately lead to biliary atresia and extrahepatic fibrosis. We treated mouse cholangiocytes in three-dimensional (3D) spheroid culture and neonatal extrahepatic duct explants with biliatresone and compounds that regulate glutathione (GSH). We examined the effects of biliatresone on SOX17 levels and determined the effects of Sox17 knockdown on cholangiocytes in 3D culture. We found that biliatresone caused disruption of cholangiocyte apical polarity and loss of monolayer integrity. Spheroids treated with biliatresone had increased permeability as shown by rhodamine efflux within 5 hours compared with untreated spheroids, which retained rhodamine for longer than 12 hours. Neonatal bile duct explants treated with the toxin showed lumen obstruction with increased subepithelial staining for α-smooth muscle actin and collagen, consistent with fibrosis. Biliatresone caused a rapid and transient decrease in GSH, which was both necessary and sufficient to mediate its effects in cholangiocyte spheroid and bile duct explant systems. It also caused a significant decrease in cholangiocyte levels of SOX17, and Sox17 knockdown in cholangiocyte spheroids mimicked the effects of biliatresone. CONCLUSION: Biliatresone decreases GSH and SOX17 in mouse cholangiocytes. In 3D cell systems, this leads to cholangiocyte monolayer damage and increased permeability; in extrahepatic bile duct explants, it leads to disruption of the extrahepatic biliary tree and subepithelial fibrosis. This mechanism may be important in understanding human biliary atresia. (Hepatology 2016;64:880-893).


Assuntos
Benzodioxóis/toxicidade , Ductos Biliares Extra-Hepáticos/efeitos dos fármacos , Atresia Biliar/induzido quimicamente , Glutationa/metabolismo , Proteínas HMGB/metabolismo , Fatores de Transcrição SOXF/metabolismo , Animais , Ductos Biliares Extra-Hepáticos/metabolismo , Ductos Biliares Extra-Hepáticos/patologia , Atresia Biliar/metabolismo , Atresia Biliar/patologia , Células Cultivadas , Modelos Animais de Doenças , Fibrose , Camundongos Endogâmicos BALB C
2.
Acta Cir Bras ; 25(4): 375-80, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20676498

RESUMO

PURPOSE: To study the influence of glutamine on functional and morphological changes of liver in the extrahepatic biliary obstruction through an experimental model in rats. METHODS: Seventy Wistar rats were divided into four groups: control (group C) fictitious operation, (group FO), submitted to laparotomy with handling of bile ducts, but without hepatic duct ligation, (group EBO) submitted to laparotomy and hepatic duct ligation, one of them submitted to supplementation with glutamine 2% (group G). The control group consisted of 6 animals. The animals from groups FO, EBO and G were divided into three groups consisting of 6 animals each, being sacrificed at 7, 14 and 21 days after operation, respectively. Blood samples were collected for biochemical analysis and a fragment of liver tissue was collected from the middle lobe for histological analysis. RESULTS: Both for biochemical analysis (BT, aspartate and alanine aminotransferase AST, ALT and alkaline phosphatase FAL) and for histopathological changes (fibrosis, portal inflammation, parenchymal inflammation, hepatocytic changes and duct proliferation), no statistical difference between groups submitted to extrahepatic biliary obstruction (EBO) with and without treatment with glutamine (G) was observed. CONCLUSION: Glutamine supplementation did not alter the prognosis of liver enzymes and histopathological changes in animals submitted to extrahepatic biliary obstruction.


Assuntos
Ductos Biliares Extra-Hepáticos/patologia , Colestase Extra-Hepática/patologia , Glutamina/administração & dosagem , Fígado/patologia , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Ductos Biliares Extra-Hepáticos/efeitos dos fármacos , Ductos Biliares Extra-Hepáticos/enzimologia , Ductos Biliares Extra-Hepáticos/fisiopatologia , Colestase Extra-Hepática/metabolismo , Colestase Extra-Hepática/fisiopatologia , Modelos Animais de Doenças , Nutrição Enteral/métodos , Ducto Hepático Comum , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/fisiopatologia , Masculino , Complicações Pós-Operatórias/prevenção & controle , Ratos , Ratos Wistar
3.
Acta cir. bras ; 25(4): 375-380, July-Aug. 2010. graf, tab
Artigo em Inglês | LILACS | ID: lil-553247

RESUMO

PURPOSE: To study the influence of glutamine on functional and morphological changes of liver in the extrahepatic biliary obstruction through an experimental model in rats. METHODS: Seventy Wistar rats were divided into four groups: control (group C) fictitious operation, (group FO), submitted to laparotomy with handling of bile ducts, but without hepatic duct ligation, (group EBO) submitted to laparotomy and hepatic duct ligation, one of them submitted to supplementation with glutamine 2 percent (group G). The control group consisted of 6 animals. The animals from groups FO, EBO and G were divided into three groups consisting of 6 animals each, being sacrificed at 7, 14 and 21 days after operation, respectively. Blood samples were collected for biochemical analysis and a fragment of liver tissue was collected from the middle lobe for histological analysis. RESULTS: Both for biochemical analysis (BT, aspartate and alanine aminotransferase AST, ALT and alkaline phosphatase FAL) and for histopathological changes (fibrosis, portal inflammation, parenchymal inflammation, hepatocytic changes and duct proliferation), no statistical difference between groups submitted to extrahepatic biliary obstruction (EBO) with and without treatment with glutamine (G) was observed. CONCLUSION: Glutamine supplementation did not alter the prognosis of liver enzymes and histopathological changes in animals submitted to extrahepatic biliary obstruction.


OBJETIVO: Estudar a influência da glutamina em alterações funcionais e morfológicas do fígado na obstrução biliar extra-hepática por meio de um modelo experimental desenvolvido em ratos. MÉTODOS: Setenta ratos Wistar distribuídos em quatro grupos: controle (grupo C); operação fictícia (grupo OF), submetido à laparotomia com manuseio das vias biliares, mas sem ligadura do ducto hepático; (grupo OBE), submetido à laparotomia exploradora e ligadura do ducto hepático, sendo um deles submetido à suplementação com glutamina a 2 por cento (grupo G). O grupo controle era composto por seis animais. Os animais dos grupos OF, OBE e G foram divididos em três grupos compostos por seis animais cada e que foram sacrificados no 7°, 14° e 21° dias após a operação, respectivamente. Foi colhido sangue para análise bioquímica e um fragmento de tecido hepático do lobo médio para estudo histológico. RESULTADOS: Tanto em relação à analise bioquímica (BT, aspartate and alanine aminotransferase AST, ALT e FAL) quanto em relação às alterações histopatológicas (fibrose, inflamação portal, inflamação parenquimatosa, alterações hepatocíticas e proliferação de ducto), não houve diferença estatística entre os grupos submetido a obstrução biliar extra-hepática sem (OBE) e com tratamento com glutamina (G). CONCLUSÃO: A suplementação com glutamina não alterou o prognóstico em relação às enzimas hepáticas e alterações histopatológicas nos animais submetidos à obstrução biliar extra-hepática.


Assuntos
Animais , Masculino , Ratos , Ductos Biliares Extra-Hepáticos/patologia , Colestase Extra-Hepática/patologia , Glutamina/administração & dosagem , Fígado/patologia , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Ductos Biliares Extra-Hepáticos/efeitos dos fármacos , Ductos Biliares Extra-Hepáticos/enzimologia , Ductos Biliares Extra-Hepáticos/fisiopatologia , Colestase Extra-Hepática/metabolismo , Colestase Extra-Hepática/fisiopatologia , Modelos Animais de Doenças , Nutrição Enteral/métodos , Ducto Hepático Comum , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/fisiopatologia , Complicações Pós-Operatórias/prevenção & controle , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA